Pharmaceutical Contract Sales Outsourcing [CSO] Market Size is valued at USD 10.80 Bn in 2024 and is predicted to reach USD 25.80 Bn by the year 2034 at a 9.2% CAGR during the forecast period for 2025-2034.
![Pharmaceutical Contract Sales Outsourcing [CSO] Market Info](https://www.insightaceanalytic.com/images_data/968670401.jpg "Pharmaceutical Contract Sales Outsourcing [CSO] Market Info")
Pharmaceutical Contract Sales Outsourcing (CSO) refers to the practice of pharmaceutical companies partnering with external organizations to handle various aspects of their sales and marketing efforts. Due to cost reductions, enhanced flexibility, and availability of specialist knowledge, this concept has gained popularity in the pharmaceutical business.
Some of the main drivers of the industry's expansion include increased new drug launches, pharmaceutical R&D activities, and consumer demand for lower in-house sales costs. The majority of medicine sales during the COVID-19 pandemic were conducted online. i.e., over the phone, during a web conference, through email, and during website involvement. Thus, it is predicted that the growing digitalization of pharmaceutical marketing and sales will constrain the market for pharmaceutical contract sales outsourcing.
Furthermore, the primary barriers to CSO's operations and compliance include rising scrutiny and regulations within the healthcare sector. On the other hand, it gives pharmaceutical businesses access to a highly qualified and specialized sales force without the need for significant recruitment and training efforts, which is one of the primary potentials in the market. In addition, industry expansion is supported by an increase in the introduction of regulatory scrutiny and the growing need to maintain competitiveness. These elements are anticipated to increase pharmaceutical businesses' demand for contract sales services and foster market expansion.
The pharmaceutical contract sales outsourcing [CSO] market is segmented on the basis of service and therapeutic area. Based on the service, the market is segmented into Personal Promotion, which again comprises Promotional Sales Team [Dedicated Sales Team, Syndicated Sales Team], Key Account Management, Vacancy Management), Non-personal Promotion (Tele-detailing, Interactive E-detailing, Customer Service, Medical Science Liaisons, Patient Engagement Services, Others) and Others. As per the therapeutic area, the market is segmented into Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others.
The non-personal promotion category is expected to hold a major share of the global pharmaceutical contract sales outsourcing [CSO] market in 2022. This is a result of a number of things, including the growing use of digital technologies, their affordability, and their increased capacity to be cost-effective. To reach healthcare practitioners and patients, pharmaceutical companies must implement new digital marketing strategies in light of the expanding usage of digital technology in healthcare.
Additionally, non-personal promotion channels like email, social media, and internet advertising offer a practical and focused means to target particular demographics. Compared to personal promotion, which involves face-to-face encounters between salespeople and healthcare professionals, non-personal promotion is frequently less expensive.
The segment oncology is estimated to grow at a rapid rate in the global pharmaceutical contract sales outsourcing [CSO] market. As a result, there is a rising need for medicines used in oncology therapies as well as other cancer treatments and therapies, which has, in turn, increased the demand for pharmaceutical contract sales outsourcing. A further factor in expanding the pharmaceutical contract sales outsourcing market in the oncology sector is the introduction of novel and cutting-edge cancer treatments, including targeted therapies and immunotherapies.
North American pharmaceutical contract sales outsourcing [CSO] market is expected to record the maximum market share in the near future. Several elements, including many pharmaceutical firms, substantial healthcare spending, and supportive governmental initiatives drive the market. The majority of the market share in North America belongs to the United States, which leads the region. With a highly advanced healthcare system that fuels demand for pharmaceutical goods and services, the United States boasts the largest pharmaceutical business in the world.
In addition, Asia-Pacific is expected to grow at the quickest rate due to a number of causes, including the ageing population and rising prevalence of chronic diseases, which drive the need for pharmaceutical goods and services. Additionally, the market is being stimulated by innovation and investment due to the industry's use of modern technology.
Furthermore, the demand for sales and marketing services is being driven by the pharmaceutical industry's growing emphasis on research and development. As a result, Asia Pacific is a crucial market for pharmaceutical contract sales outsourcing (CSO) and is anticipated to expand in the future.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 10.80 Bn |
|
Revenue Forecast In 2034 |
USD 25.80 Bn |
|
Growth Rate CAGR |
CAGR of 9.2% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Service, Therapeutic Area |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia |
|
Competitive Landscape |
Ashfield (UDG Healthcare plc), inVentiv Health, Inc. (Syneos Health), IQVIA, Granard Pharmaceutical Sales & Marketing, Vanguard Pharma, Inc., GTS Solution, EVERSANA, MaBiCo, QFR Solutions, Pharmaforce Ireland Ltd., Sales Focus, Inc., Amplity Health and PharmaLex GmbH. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Pharmaceutical Contract Sales Outsourcing [CSO] Market Snapshot
Chapter 4. Global Pharmaceutical Contract Sales Outsourcing [CSO] Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Service Estimates & Trend Analysis
5.1. By Service, & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Service:
5.2.1. Personal Promotion
5.2.1.1. Promotional Sales Team
5.2.1.1.1. Dedicated Sales Team
5.2.1.1.2. Syndicated Sales Team
5.2.1.2. Key Account Management
5.2.1.3. Vacancy Management
5.2.2. Non-personal Promotion
5.2.2.1. Tele-detailing
5.2.2.2. Interactive E-detailing
5.2.2.3. Customer Service
5.2.2.4. Medical Science Liaisons
5.2.2.5. Patient Engagement Services
5.2.2.6. Others
5.2.3. Others
Chapter 6. Market Segmentation 2: By Therapeutic Area Estimates & Trend Analysis
6.1. By Therapeutic Area & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Therapeutic Area:
6.2.1. Cardiovascular Disorders
6.2.2. Oncology
6.2.3. Metabolic Disorders
6.2.4. Neurology
6.2.5. Orthopedic Diseases
6.2.6. Infectious Diseases
6.2.7. Others
Chapter 7. Pharmaceutical Contract Sales Outsourcing [CSO] Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Pharmaceutical Contract Sales Outsourcing [CSO] Market revenue (US$ Million) estimates and forecasts By Service, 2021-2034
7.1.2. North America Pharmaceutical Contract Sales Outsourcing [CSO] Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034
7.1.3. North America Pharmaceutical Contract Sales Outsourcing [CSO] Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe Pharmaceutical Contract Sales Outsourcing [CSO] Market revenue (US$ Million) By Service, 2021-2034
7.2.2. Europe Pharmaceutical Contract Sales Outsourcing [CSO] Market revenue (US$ Million) By Therapeutic Area, 2021-2034
7.2.3. Europe Pharmaceutical Contract Sales Outsourcing [CSO] Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Pharmaceutical Contract Sales Outsourcing [CSO] Market revenue (US$ Million) By Service, 2021-2034
7.3.2. Asia Pacific Pharmaceutical Contract Sales Outsourcing [CSO] Market revenue (US$ Million) By Therapeutic Area, 2021-2034
7.3.3. Asia Pacific Pharmaceutical Contract Sales Outsourcing [CSO] Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Pharmaceutical Contract Sales Outsourcing [CSO] Market revenue (US$ Million) By Service, (US$ Million) 2021-2034
7.4.2. Latin America Pharmaceutical Contract Sales Outsourcing [CSO] Market revenue (US$ Million) By Therapeutic Area, (US$ Million) 2021-2034
7.4.3. Latin America Pharmaceutical Contract Sales Outsourcing [CSO] Market revenue (US$ Million) by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Pharmaceutical Contract Sales Outsourcing [CSO] Market revenue (US$ Million) By Service, (US$ Million) 2021-2034
7.5.2. Middle East & Africa Pharmaceutical Contract Sales Outsourcing [CSO] Market revenue (US$ Million) By Therapeutic Area, (US$ Million) 2021-2034
7.5.3. Middle East & Africa Pharmaceutical Contract Sales Outsourcing [CSO] Market revenue (US$ Million) by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Ashfield (UDG Healthcare plc)
8.2.2. inVentiv Health, Inc. (Syneos Health)
8.2.3. IQVIA
8.2.4. Granard Pharmaceutical Sales & Marketing
8.2.5. Vanguard Pharma, Inc.
8.2.6. GTS Solution
8.2.7. EVERSANA
8.2.8. MaBiCo
8.2.9. QFR Solutions
8.2.10. Pharmaforce Ireland Ltd.
8.2.11. Sales Focus, Inc.
8.2.12. Amplity Health
8.2.13. PharmaLex GmbH
Pharmaceutical Contract Sales Outsourcing [CSO] Market By Service
![Pharmaceutical Contract Sales Outsourcing [CSO] Market Segment](https://www.insightaceanalytic.com/images_data/922263688.JPG "Pharmaceutical Contract Sales Outsourcing [CSO] Market Segment")
Pharmaceutical Contract Sales Outsourcing [CSO] Market By Therapeutic Area
Pharmaceutical Contract Sales Outsourcing [CSO] Market By Region
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
